Clinical characteristics, management, and prognosis of ipilimumab-induced hypophysitis: a retrospective analysis of 76 cases
-
By
-
Ling Wu
-
Yuping Yang
-
Qiongli Su
-
June 30, 2026
-
Clinical Scorecard: Clinical Features, Treatment Strategies, and Outcomes of Hypophysitis Induced by Ipilimumab: A Retrospective Study of 76 Cases
At a Glance
| Category | Detail |
|---|
| Condition | Ipilimumab-induced hypophysitis |
| Key Mechanisms | Immune-mediated inflammation of the pituitary gland due to CTLA-4 inhibition |
| Target Population | Patients receiving ipilimumab for advanced malignancies |
| Care Setting | Oncology and endocrinology clinics |
Key Highlights
- Median age of patients was 58 years, with 61.8% being male.
- Common symptoms included headache (68.0%) and fatigue (64.0%).
- Secondary adrenal insufficiency was observed in 93.4% of evaluated patients.
- Pituitary enlargement was noted in 71.0% of patients undergoing MRI.
- Clinical improvement occurred in 82.9% of patients, but complete hormonal recovery was rare (7.9%).
Guideline-Based Recommendations
Diagnosis
- Diagnosis is supported by clinical symptoms, biochemical tests, and MRI findings.
Management
- Glucocorticoid replacement is the primary treatment for hypophysitis.
Monitoring & Follow-up
- Long-term endocrine monitoring is recommended due to common persistent hormonal deficiencies.
Risks
- Ipilimumab rechallenge is uncommon and should be approached with caution.
Patient & Prescribing Data
Patients treated with ipilimumab for advanced malignancies.
Hormone replacement therapy is essential for managing secondary adrenal insufficiency and other endocrine dysfunctions.
Clinical Best Practices
- Early recognition of symptoms is crucial for timely management.
- Regular follow-up for endocrine function is necessary after treatment.
Related Resources & Content
